Shares of Keryx Biopharmaceuticals (KERX) shed 2.2% premarket after taking on a number of...

|About: Keryx Biopharmaceuticals,... (KERX)|By:, SA News Editor

Shares of Keryx Biopharmaceuticals (KERX) shed 2.2% premarket after taking on a number of downgrades from analysts. The cratering of shares this week following the failure of its Perifisone drug serves as a stark reminder of the great risk/reward tradeoff in the biotech/small pharma sector, according to VFC Stock House.